Chayada Sajjaweerawan

Chayada Sajjaweerawan

Auto-generated profile, based on publicly available information

Chayada Sajjaweerawan

Department of Retrovirology, Walter Reed Army Institute of Research–Armed Forces Research Institute of Medical Sciences , Bangkok

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
SVSinmanus Vimonpatranon
Sinmanus Vimonpatranon
ASAloysious Ssemaganda
Aloysious Ssemaganda
YPYuwadee Phuang-Ngern
Yuwadee Phuang-Ngern
CSChayada Sajjaweerawan
Chayada Sajjaweerawan
PSPutita Saetun
Putita Saetun
RGRV254/SEARCH010 and RV304/SEARCH013 study groups
RV254/SEARCH010 and RV304/SEARCH013 study groups
Background: Tissue-resident memory CD4+ T (CD4+ TRM) cells are long-lived, seldom-circulating cells that reside for long periods in most tissues. TRM cells can mount rapid, antigen-specific responses to pathogens and contribute to mucosal barrier homeostasis by regulating commensal interactions. At the intestinal mucosa, the main site of early human immunodeficiency virus (HIV) replication, CD4+ TRM cells may serve as virus targets; however, limited data are available regarding their dynamics during acute HIV-1 infection and antiretroviral treatment. Methods: This was a nested cross-sectional study within a longitudinal cohort. Results: Sigmoid CD4+ TRM (CD69+CD103+) cells had a higher expression of CCR5 than CD4+ non-TRM (CD69−CD103−) cells, suggestive of increased susceptibility to HIV-1 infection. Consistent with this, sigmoid CD4+ TRM but not CD4+ non-TRM cells were depleted/nonreplenished despite long-term ART, regardless of the Fiebig stage at which treatment was initiated during acute HIV infection. In contrast, overall sigmoid CD4+ T cells were comparable in abundance with people living without HIV if treatment was initiated at Fiebig stage I or II, but they were significantly decreased if treatment was initiated at Fiebig stage III or beyond, suggesting preferential early depletion/nonreplenishment of CD4+ TRM cells. The loss/nonreplenishment of sigmoid CD4+ TRM cells was associated with a lower abundance of that short-chain fatty acid–producing commensal bacteria that are crucial for the maintenance of mucosal homeostasis, a higher abundance of opportunistic pathobionts Desulfovibrio, and increased soluble biomarkers of systemic inflammation that drive non-AIDS mortality. Conclusions: Sigmoid CD4+ TRM cells may be early mucosal targets of HIV-1 infection and that their persistent depletion contributes to decreased mucosal barrier function, warranting development of therapeutic strategies that can restore CD4+ TRM cells during HIV treatment.